ECSP15042898A - Péptidos y composiciones para el tratamiento de daño articular - Google Patents

Péptidos y composiciones para el tratamiento de daño articular

Info

Publication number
ECSP15042898A
ECSP15042898A ECIEPI201542898A ECPI201542898A ECSP15042898A EC SP15042898 A ECSP15042898 A EC SP15042898A EC IEPI201542898 A ECIEPI201542898 A EC IEPI201542898A EC PI201542898 A ECPI201542898 A EC PI201542898A EC SP15042898 A ECSP15042898 A EC SP15042898A
Authority
EC
Ecuador
Prior art keywords
amino acid
acid sequence
seq
determined
angptl3
Prior art date
Application number
ECIEPI201542898A
Other languages
English (en)
Inventor
Jian Shi
Kristen Johnson
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of ECSP15042898A publication Critical patent/ECSP15042898A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1891—Angiogenesic factors; Angiogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/32—Bones; Osteocytes; Osteoblasts; Tendons; Tenocytes; Teeth; Odontoblasts; Cartilage; Chondrocytes; Synovial membrane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/01—Hydrolysed proteins; Derivatives thereof
    • A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
    • A61K38/014—Hydrolysed proteins; Derivatives thereof from animals from connective tissue peptides, e.g. gelatin, collagen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/225—Calcitonin gene related peptide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/515—Angiogenesic factors; Angiogenin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0655—Chondrocytes; Cartilage
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/17—Angiopoietin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/13—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells
    • C12N2506/1346—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells from mesenchymal stem cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Vascular Medicine (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Endocrinology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)

Abstract

La presente invención se refiere a la identificación de nuevas variantes de polipéptidos y proteínas de angiopoyetina-tipo 3 (ANGPTL3) que tienen propiedades farmacéuticas mejoradas, por ejemplo, son más estables, menos susceptibles a la proteólisis y degradación enzimática que ANGPTL3 de tipo salvaje. También se proporcionan composiciones farmacéuticas y métodos para el tratamiento del daño articular o lesiones articulares, y los métodos para mejorar o prevenir artritis, daño en articulaciones o lesión de articulaciones en un mamífero. Por lo tanto, se proporcionan polipéptidos resistentes a la proteasa que comprenden una secuencia de aminoácidos que tiene al menos 95% de identidad de secuencia de aminoácidos, o al menos 96%, 97%, 98%, 99% o 100% de identidad de secuencia de aminoácidos con una secuencia de aminoácidos seleccionada de cualquiera o varias de las secuencias de la Tabla 1, y tal cual se describe adicionalmente en este documento. Los polipéptidos modificados de la Tabla 1 incluyen un aminoácido que es un aminoácido polar que no sea K o R en la posición 423, según se determina con referencia a la secuencia polipeptídica ANGPTL3 de longitud completa, SEQ ID NO: 1. En algunas realizaciones, el aminoácido en la posición 423 como se determina con referencia a la SEC ID No: 1 es Q o S. En ciertas realizaciones, el aminoácido en la posición 423 como se determina con referencia a la SEC ID No: 1 es Q. En ciertas realizaciones, el aminoácido en la posición 423 como
ECIEPI201542898A 2013-03-08 2015-10-08 Péptidos y composiciones para el tratamiento de daño articular ECSP15042898A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361775400P 2013-03-08 2013-03-08
US201461938123P 2014-02-10 2014-02-10

Publications (1)

Publication Number Publication Date
ECSP15042898A true ECSP15042898A (es) 2019-03-29

Family

ID=50390286

Family Applications (1)

Application Number Title Priority Date Filing Date
ECIEPI201542898A ECSP15042898A (es) 2013-03-08 2015-10-08 Péptidos y composiciones para el tratamiento de daño articular

Country Status (39)

Country Link
US (4) US9649359B2 (es)
EP (2) EP2964250B1 (es)
JP (3) JP6567429B2 (es)
KR (1) KR102267341B1 (es)
CN (2) CN111808182A (es)
AP (1) AP2015008675A0 (es)
AU (3) AU2014225348B2 (es)
BR (2) BR112015021269B1 (es)
CA (1) CA2903448C (es)
CL (1) CL2015002443A1 (es)
CO (1) CO7461145A2 (es)
CR (2) CR20200290A (es)
CU (1) CU24301B1 (es)
CY (1) CY1120729T1 (es)
DK (1) DK2964250T3 (es)
EA (1) EA035158B1 (es)
EC (1) ECSP15042898A (es)
ES (1) ES2684349T3 (es)
HK (1) HK1214754A1 (es)
HR (1) HRP20181269T1 (es)
HU (1) HUE038499T2 (es)
IL (1) IL240727B (es)
JO (1) JO3564B1 (es)
LT (1) LT2964250T (es)
MX (1) MX365157B (es)
MY (1) MY173172A (es)
NZ (1) NZ711037A (es)
PE (1) PE20151528A1 (es)
PH (1) PH12015501983A1 (es)
PL (1) PL2964250T3 (es)
PT (1) PT2964250T (es)
RS (1) RS57446B1 (es)
SG (1) SG11201506490TA (es)
SI (1) SI2964250T1 (es)
TN (1) TN2015000385A1 (es)
TW (1) TWI634124B (es)
UY (1) UY35368A (es)
WO (1) WO2014138687A1 (es)
ZA (1) ZA201505966B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2012000707A (es) 2009-07-14 2012-03-21 Scripps Research Inst Diferenciacion de celula madre mesenquimatica.
JO3564B1 (ar) 2013-03-08 2020-07-05 Novartis Ag ببتيدات وتركيبات لعلاج ضرر المفاصل
US9301971B2 (en) 2013-03-08 2016-04-05 Novartis Ag Peptides and compositions for treatment of joint damage
WO2018078706A1 (ja) 2016-10-24 2018-05-03 住友化学株式会社 セパレータ、およびセパレータを含む二次電池
AU2017357785A1 (en) 2016-11-14 2019-04-11 Novartis Ag Methods and compositions for treatment of cartilage damage and arthritis
CN108530619B (zh) * 2017-03-01 2020-12-08 北京大学第三医院 功能化氨基酸、制备方法及由其制得的功能化氨基酸水凝胶
WO2020021447A1 (en) 2018-07-25 2020-01-30 Novartis Ag Nlrp3 inflammasome inhibitors
TW202027794A (zh) * 2018-10-03 2020-08-01 瑞士商諾華公司 血管生成素樣３多肽之持續遞送
AR119731A1 (es) 2019-05-17 2022-01-05 Novartis Ag Inhibidores del inflamasoma nlrp3
CN111973617A (zh) * 2019-05-23 2020-11-24 苏州瑞博生物技术股份有限公司 核酸、药物组合物与缀合物及制备方法和用途
US20220380425A1 (en) * 2019-07-04 2022-12-01 Cadila Healthcare Limited Angptl3 based vaccine for the treatment of liver disease
KR102577697B1 (ko) * 2019-11-13 2023-09-14 주식회사 나이벡 염증 및 상처 치료용 펩타이드
JP7298496B2 (ja) 2020-01-31 2023-06-27 トヨタ自動車株式会社 車両
WO2022249040A1 (en) 2021-05-24 2022-12-01 Novartis Ag Methods for the treatment of osteoarthritis
TW202306970A (zh) 2021-05-24 2023-02-16 瑞士商諾華公司 用於治療骨關節炎之方法
CN113683681B (zh) * 2021-09-15 2023-10-03 山西锦波生物医药股份有限公司 一种重组i型人源化胶原蛋白c1l3t及其制备方法和用途
CN113683678B (zh) * 2021-09-15 2023-11-24 山西锦波生物医药股份有限公司 一种重组i型人源化胶原蛋白c1l2t及其制备方法和用途
WO2023084388A1 (en) 2021-11-10 2023-05-19 Novartis Ag Methods for determining the biological activity of angptl polypeptides
CN114377202B (zh) * 2021-12-16 2023-01-24 方向前 适用于软骨再生的功能化自组装miRNA/多肽复合水凝胶及其制备方法
TW202406550A (zh) 2022-08-03 2024-02-16 瑞士商諾華公司 Ｎｌｒｐ３炎性小體抑制劑

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308236D0 (en) * 1983-03-25 1983-05-05 Celltech Ltd Dna vectors
US5462990A (en) 1990-10-15 1995-10-31 Board Of Regents, The University Of Texas System Multifunctional organic polymers
US5288931A (en) 1991-12-06 1994-02-22 Genentech, Inc. Method for refolding insoluble, misfolded insulin-like growth factor-I into an active conformation
US6447796B1 (en) 1994-05-16 2002-09-10 The United States Of America As Represented By The Secretary Of The Army Sustained release hydrophobic bioactive PLGA microspheres
US6030831A (en) 1997-09-19 2000-02-29 Genetech, Inc. Tie ligand homologues
WO1999055869A1 (en) 1998-04-27 1999-11-04 Zymogenetics, Inc. Novel polypeptide growth factors and materials and methods for making them
CA2332109A1 (en) 1998-05-12 1999-11-18 Human Genome Sciences, Inc. 97 human secreted proteins
AU4643699A (en) 1998-06-24 2000-01-10 Compugen Ltd. Angiopoietin-like growth factor sequences
JP2003531811A (ja) 1999-03-08 2003-10-28 ジェネンテック・インコーポレーテッド 血管形成及び心臓血管新生の促進又は阻害
JP2002537828A (ja) 1999-03-10 2002-11-12 フォゲン リミティド 細胞への物質のデリバリー
GB9912350D0 (en) 1999-05-26 1999-07-28 European Molecular Biology Lab Embl Modified cytokine
ES2291198T3 (es) 1999-07-20 2008-03-01 Genentech, Inc. Composiciones y procedimientos para el tratamiento de enfermedades de tipo inmunologico.
US20030013649A1 (en) 2000-01-31 2003-01-16 Rosen Craig A. Nucleic acids, proteins, and antibodies
ATE389719T1 (de) 2000-10-16 2008-04-15 Genentech Inc Behandlungsverfahren mit wisp-polypeptiden
US20030144498A1 (en) 2000-10-16 2003-07-31 Audrey Goddard TIE ligand homologues
US20020130430A1 (en) 2000-12-29 2002-09-19 Castor Trevor Percival Methods for making polymer microspheres/nanospheres and encapsulating therapeutic proteins and other products
US20030027751A1 (en) 2001-04-10 2003-02-06 Genvec, Inc. VEGF fusion proteins
WO2002085923A2 (en) 2001-04-19 2002-10-31 The Scripps Research Institute In vivo incorporation of unnatural amino acids
US20030194798A1 (en) 2001-05-24 2003-10-16 Surber Mark W. Minicell compositions and methods
FI117667B (fi) 2001-07-05 2007-01-15 Univ Zuerich Farmaseuttinen koostumus, joka soveltuu käytettäväksi ortopediassa ja hammaslääketieteessä
JP5105696B2 (ja) 2001-11-16 2012-12-26 ジェネンテック， インコーポレイテッド アンジオポエチン様タンパク質３Ａｎｇｐｔｌ３含有組成物とその使用方法
US7060498B1 (en) 2001-11-28 2006-06-13 Genta Salus Llc Polycationic water soluble copolymer and method for transferring polyanionic macromolecules across biological barriers
US7141540B2 (en) 2001-11-30 2006-11-28 Genta Salus Llc Cyclodextrin grafted biocompatible amphilphilic polymer and methods of preparation and use thereof
BR0314172A (pt) 2002-09-09 2005-07-26 Nektar Therapeutics Al Corp Polìmero solúvel em água, composição, forma de hidrato ou acetal, composto,composição, usos do composto e do conjugado, e, processo para preparar o conjugado
DK1578949T3 (da) 2002-10-16 2009-07-27 Scripps Research Inst Stedspecifik optagelse af keto-aminnosyrer hos proteiner
CA2500653A1 (en) 2002-10-16 2004-04-29 The Scripps Research Institute Glycoprotein synthesis
JP5642916B2 (ja) 2003-04-17 2014-12-17 ザ スクリプス リサーチ インスティテュート 真核遺伝コードの拡張
BRPI0412272A (pt) 2003-07-07 2006-09-05 Scripps Research Inst composições de pares de lisil-trna e aminoacil-trna sintetase ortogonais e usos destes
US20060160175A1 (en) 2003-07-07 2006-07-20 The Scripps Research Institute Compositions of orthogonal leucyl-trna and aminoacyl-trna synthetase pairs and uses thereof
WO2005007624A2 (en) 2003-07-07 2005-01-27 The Scripps Research Institute Compositions of orthogonal glutamyl-trna and aminoacyl trna synthetase pairs and uses thereof
ES2519444T3 (es) 2004-09-21 2014-11-07 The Scripps Research Institute Incorporación in vivo de alquinil aminoácidos a proteínas en eubacterias
AU2005330514B2 (en) 2004-10-27 2011-05-12 The Scripps Research Institute Orthogonal translation components for the in vivo incorporation of unnatural amino acids
EP1863340A2 (en) 2005-03-11 2007-12-12 Genentech, Inc. Gene disruptions, compositions and methods relating thereto
US7807464B2 (en) 2005-05-24 2010-10-05 Whitehead Institute For Biomedical Research Methods for expansion and analysis of cultured hematopoietic stem cells
US8198044B2 (en) 2006-03-09 2012-06-12 The Scripps Research Institute Systems for the expression of orthogonal translation components eubacterial host cells
WO2008069348A1 (en) 2006-12-06 2008-06-12 Seikagaku Corporation Pharmaceutical agent having long-lasting effect of treating arthritic disorders
BRPI0720218A2 (pt) 2006-12-08 2013-12-24 Lexicon Pharmaceuticals Inc Anticorpos monoclonais contra angptl3
EP2118150B1 (en) 2007-02-14 2015-09-23 Biocompatibles UK Limited Derivatisation of biological molecules
WO2008137641A2 (en) 2007-05-04 2008-11-13 Whitehead Institute For Biomedical Research Ex vivo expansion of human hematopoietic stem cells
MX2012000707A (es) * 2009-07-14 2012-03-21 Scripps Research Inst Diferenciacion de celula madre mesenquimatica.
CA2826142A1 (en) 2011-02-03 2012-08-09 Xoma Technology Ltd. Methods and materials for enhancing functional protein expression in bacteria
WO2012129562A2 (en) 2011-03-24 2012-09-27 The Scripps Research Institute Compounds and methods for inducing chondrogenesis
CN104619727B (zh) 2012-06-25 2019-04-05 布里格姆及妇女医院股份有限公司 靶向治疗
JO3564B1 (ar) 2013-03-08 2020-07-05 Novartis Ag ببتيدات وتركيبات لعلاج ضرر المفاصل
US9301971B2 (en) 2013-03-08 2016-04-05 Novartis Ag Peptides and compositions for treatment of joint damage

Also Published As

Publication number Publication date
JP2016510763A (ja) 2016-04-11
NZ711037A (en) 2018-07-27
CY1120729T1 (el) 2019-12-11
KR20150125712A (ko) 2015-11-09
PH12015501983B1 (en) 2016-01-11
AU2014225348A1 (en) 2015-09-10
CO7461145A2 (es) 2015-11-30
TN2015000385A1 (en) 2017-01-03
AU2016203028A1 (en) 2016-05-26
JP6567429B2 (ja) 2019-08-28
JP2021178841A (ja) 2021-11-18
CA2903448C (en) 2021-03-23
LT2964250T (lt) 2018-07-25
AU2016203028B2 (en) 2017-02-02
HRP20181269T1 (hr) 2018-10-19
WO2014138687A1 (en) 2014-09-12
CN111808182A (zh) 2020-10-23
JP6918871B2 (ja) 2021-08-11
US20170252407A1 (en) 2017-09-07
ES2684349T3 (es) 2018-10-02
IL240727B (en) 2019-12-31
EA035158B1 (ru) 2020-05-06
BR122016021558B1 (pt) 2023-03-28
US9649359B2 (en) 2017-05-16
TW201444865A (zh) 2014-12-01
BR122016021558A2 (pt) 2019-07-30
EP2964250B1 (en) 2018-05-16
MX2015011963A (es) 2015-12-09
RS57446B1 (sr) 2018-09-28
PE20151528A1 (es) 2015-11-14
SI2964250T1 (sl) 2018-11-30
DK2964250T3 (da) 2018-08-06
AU2016203028C1 (en) 2017-06-01
US11179442B2 (en) 2021-11-23
HK1214754A1 (zh) 2016-08-05
US10328126B2 (en) 2019-06-25
BR112015021269A2 (pt) 2017-10-10
CL2015002443A1 (es) 2016-05-20
MY173172A (en) 2020-01-02
AU2016277608B2 (en) 2018-04-05
EA201591661A1 (ru) 2015-12-30
EP3391900A1 (en) 2018-10-24
PT2964250T (pt) 2018-10-19
PH12015501983A1 (en) 2016-01-11
UY35368A (es) 2014-10-31
AU2014225348B2 (en) 2016-03-31
US20160008433A1 (en) 2016-01-14
SG11201506490TA (en) 2015-09-29
KR102267341B1 (ko) 2021-06-21
JP2020015725A (ja) 2020-01-30
US20220184182A1 (en) 2022-06-16
AP2015008675A0 (en) 2015-08-31
CN105025917A (zh) 2015-11-04
CR20200290A (es) 2020-08-27
IL240727A0 (en) 2015-10-29
CN105025917B (zh) 2020-08-18
CU20150097A7 (es) 2016-05-30
CR20150466A (es) 2015-10-27
HUE038499T2 (hu) 2018-10-29
PL2964250T3 (pl) 2018-10-31
EP2964250A1 (en) 2016-01-13
CU24301B1 (es) 2017-12-08
AU2016277608A1 (en) 2017-01-12
CA2903448A1 (en) 2014-09-12
US20200268849A1 (en) 2020-08-27
JO3564B1 (ar) 2020-07-05
ZA201505966B (en) 2017-03-29
MX365157B (es) 2019-05-24
BR112015021269B1 (pt) 2023-04-11
TWI634124B (zh) 2018-09-01

Similar Documents

Publication Publication Date Title
ECSP15042898A (es) Péptidos y composiciones para el tratamiento de daño articular
EA201791426A1 (ru) Полипептид и иммуномодуляция
UY39119A (es) Proteínas de fusión para tratar trastornos metabólicos
PE20130041A1 (es) Proteinas de dominio de andamiaje de fibronectina que se unen a interleucina 23 (il-23)
TN2017000085A1 (en) Polypeptide having a polyester degrading activity and uses thereof
ES2722773T3 (es) Polipéptidos de fHbp meningocócicos modificados
BR112017019625A2 (pt) udp-glicosiltransferases
CO2018009120A2 (es) Genes del factor viii optimizados
EA201792245A1 (ru) Биоконъюгаты и их применения
ES2624531T3 (es) Polipéptidos que tienen actividad de lisozima y polinucleótidos que codifican los mismos
CL2017001883A1 (es) Compuestos antisenescentes y usos de los mismos
ES2565060T3 (es) Polipéptidos que tienen actividad de glucoamilasa y polinucleótidos que codifican los mismos
AR120721A2 (es) Péptidos y composiciones para el tratamiento de daño articular
GT201700224A (es) Proteína de unión a rgma y su uso
EA201491277A1 (ru) Противораковый слитый белок
EA201791238A1 (ru) Способы и композиции, в которых используются варианты полипептидов klotho
UY36565A (es) Variantes de polipéptidos que dividen toxinas de fusarium, aditivo que contiene estas variantes y su uso, asi como procedimientos para la division de toxinas de fusarium
BR112017018703A2 (pt) peptídeo derivado de gpc3, composição farmacêutica para tratamento ou prevenção de câncer usando o mesmo, indutor de imunidade, e método para produzir células de apresentação de antígeno
EA201691011A1 (ru) Последовательность модифицированного эндолизина el188
DOP2017000287A (es) Analogos glp-1 lipidados resistentes a proteasa
EA201590601A1 (ru) Применение pedf-производных полипептидов для лечения остеоартрита
CO2017011431A2 (es) Proteínas de fusión de receptor de factor de crecimiento epidermal variante iii - mesotelina
MY195726A (en) Steviol Glycoside Transport
EP4043558A3 (en) Kaurenoic acid hydroxylases
BR112014028130A2 (pt) Sal de cloridrato de um peptídeo, composição farmacêutica, uso de um sal de cloridrato, uso de uma composição farmacêutica, e, método para evitar ou tratar alergia a gatos